Safety and Efficacy of Ruxolitinib for COVID-19

Study Overview
=================
Brief Summary
-----------------
This study plans to learn more about the effects of a medicine called ruxolitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ruxolitinib is FDA-approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. This study intends to define the impact of ruxolitinib on the severity and progression of COVID-19. This drug might to lower the hyperinflammation caused by the virus, which would prevent damage to the lungs and possibly other organs. The study will recruit patients who have been diagnosed with COVID-19. The goal is to recruit 80 patients.

Detailed Description
-----------------
This is an adaptive Phase 2/3 clinical trial, with a focus on the assessment of safety in the first 20 participants (Phase 2), followed by a much broader assessment of efficacy, while continuing to monitor safety, in an additional 60 participants (Phase 3, total participants across Phase 2/3 n=80). Both phases are single arm, open label, and occur at a single site at the University of Colorado Hospital (UCH). Data from participants in this study will be compared with data from other COVID-19 patients not receiving ruxolitinib. Study participants will receive 10 mg twice daily of ruxolitinib for 14 days and will be followed for up to 29 days.

Official Title
-----------------
Safety and Efficacy of Ruxolitinib for COVID-19

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Ruxolitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18 - 89 years at time of enrollment Hospitalized (or documented plan to hospitalize if patient is in the emergency department) with symptoms suggestive of COVID-19 lllness of any duration that meets each of the following: Evidence of pneumonia, including radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or clinical assessment (rales/crackles on exam) Requires supportive care, including non-invasive supplemental oxygen Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay within 7 days of enrollment Understands and agrees to comply with planned study procedures Provides informed consent signed by study patient or legally acceptable representative Exclusion Criteria: Absolute platelet counts are less than 75 x 10^9/L Absolute neutrophil count is less than 0.5 x 10^9/L Hemoglobin is less than 8 g/dL Severe renal impairment defined by serum creatinine greater than 2 mg/dL or CrCl less than 30 mL/min Treatment with other JAK inhibitors, strong CYP3A4 inhibitors, biologic disease-modifying anti-rheumatic drugs (DMARDs, including anti-IL-6 or anti-IL-6R antibodies), or potent immunosuppressants such as azathioprine and cyclosporine concurrently or within the past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral activity. History of HIV infection and on active immunosuppressant therapy Current hematological or solid organ malignancy and on active immunosuppressant therapy Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal infection Pregnancy or breast feeding Known allergy to ruxolitinib In the opinion of the investigator, they are unlikely to survive for >48 hours from screening Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study Additional Exclusion Criteria for Phase 2 only: Invasive oxygen supplementation, including mechanical ventilation and extracorporeal membrane oxygenation (ECMO)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: This is a single arm, open label, single site study. Data from participants in this study with data from other COVID-19 patients not receiving ruxolitinib.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ruxolitinib<br>This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29. | Drug: Ruxolitinib<br>* Participants will receive 10 mg ruxolitinib twice daily.<br>* Other names: Jakavi;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs) | Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening. AEs will be collected and graded daily and cumulative incidence will be reported. | Day 0 (screening) through Day 29 | 
| Phase 2: Cumulative incidence of serious adverse events (SAEs) | An SAE is defined as an AE that is life-threatening or results in death, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. SAEs will be collected and graded daily and cumulative incidence will be reported. | Day 0 (screening) through Day 29 | 
| Phase 2: Changes in white blood cell count (CBC) through Day 15 | Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as standard of care (SOC). Mean changes from baseline to Day 15 will be reported. | Day 1 to Day 15 | 
| Phase 2: Changes in hemoglobin through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in platelets through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in creatinine through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in glucose through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in prothrombin time (PT) through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in total bilirubin through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in ALT through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in AST through Day 15 |  | Day 1 to Day 15 | 
| Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS) | Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as SOC. Mean changes from baseline to EOS will be reported. | Day through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in hemoglobin through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in platelets through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in creatinine through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in glucose through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in prothrombin time (PT) though End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in total bilirubin through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in ALT through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 2: Changes in AST through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15 | The 8-point ordinal scale described below, where a lower score indicates a worse outcome, will be performed daily or as recommended by participant's physician as SOC. The percent of participants scored at each severity will be reported on Day 15. The 8-point ordinal scale is as follows: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities | Day 15 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase 2: Change in the 8-point ordinal scale |  | Day 1 to Day 29 | 
| Phase 2: Change in National Early Warning Score (NEWS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Change in the 8-point ordinal scale |  | Day 1 to Day 29 | 
| Phase 3: Change in National Early Warning Score (NEWS) |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Time to an improvement of one category using the 8-point ordinal scale |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Time to an improvement of two categories using the 8-point ordinal scale |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs) |  | Day 0 (screening) through Day 29 | 
| Phase 3: Cumulative incidence of serious adverse events (SAEs) |  | Day 0 (screening) through Day 29 | 
| Phase 3: Duration of hospitalization |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Duration of new oxygen use |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Duration of new ventilator or ECMO use |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Incidence of new oxygen use |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Incidence of new ventilator use |  | Day 1 to Day 29 or hospital discharge, whichever is first | 
| Phase 3: Number of oxygen free days |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Number of ventilator or ECMO free days |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: 14 day mortality rate |  | Day 1 through Day 15 | 
| Phase 3: 28 day mortality rate |  | Day 1 through Day 29 | 
| Phase 3: Changes in white blood cell count (CBC) through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in hemoglobin through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in platelets through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in creatinine through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in glucose through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in prothrombin time (PT) through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in total bilirubin through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in ALT through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in AST through Day 15 |  | Day 1 to Day 15 | 
| Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS) | Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as SOC. Mean changes from baseline to EOS will be reported. | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in hemoglobin through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in platelets through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in creatinine through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in glucose through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in prothrombin time (PT) though End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in total bilirubin through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in ALT through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 
| Phase 3: Changes in AST through End of Study (EOS) |  | Day 1 through Day 29 or hospital discharge, whichever is first | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
JAK inhibitor, SARS-CoV-2, inflammation, cytokine release syndrome